Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review.

Autor: Alatorre JA; National Institute of Respiratory Diseases, Mexico City, Mexico., Campos-Gómez S; Department of Medical Oncology, State Oncology Center, Social Security Institute of the State of Mexico and Municipalities, Mexico City, State of Mexico, Mexico., De la Mora E; Jalisco Cancer Institute, Jalisco, Mexico., Novick D; Eli Lilly and Company, Surrey, UK. novick_diego@lilly.com., Cruz A; Eli Lilly and Company, Mexico City, Mexico., Iglesias-Chiesa JM; ZEED Pharmaceutical Solutions, Mexico City, Mexico.
Jazyk: angličtina
Zdroj: PharmacoEconomics - open [Pharmacoecon Open] 2020 Jun; Vol. 4 (2), pp. 381-388.
DOI: 10.1007/s41669-019-00174-x
Abstrakt: Background: The available evidence regarding the clinical characteristics, treatment patterns, adverse events (AEs), and costs of treating patients with stage IV non-small cell lung cancer (NSCLC) in Mexico is scarce.
Objective: Our objective was to describe the clinical characteristics, treatment patterns, and direct costs associated with Mexican patients diagnosed with stage IV NSCLC who had completed two or more lines of systemic antineoplastic treatment.
Methods: A multicenter retrospective cohort study was designed to collect data from the medical records of patients treated at tertiary-level public hospitals in Mexico (multicenter chart review). We calculated costs from the viewpoint of payers based on data regarding therapy and service utilization.
Results: A total of 115 patients were included. Median patient age was 61 years (interquartile range [IQR] 52.4-68.5), and 51.3% were female. The most common NSCLC type was non-squamous (92.2%), and the typical histology was adenocarcinoma (88.7%). All patients received first- and second-line therapy: 54.78% completed a third-line, 27.82% a fourth-line, 7.82% a fifth-line, 2.6% a sixth-line, and 1.7% a seventh-line active therapy. Carboplatin was the most frequently used therapy (28.6%) followed by docetaxel (23.3%), nivolumab (16.7%), and irinotecan (13.3%). AEs occurred in 53% of the patients and none was fatal. In total, 59 patients (51.3%) required hospitalization during the observation period. The median cost per patient was $US7039.40, with a minimum of $US628.30 and a maximum of $US3,557,364.20. Median overall survival of the cohort was 12 months (95% confidence interval 9.8-14.1).
Conclusions: In Mexico, NSCLC is usually diagnosed at stage IV. This study shows considerable variation in chemotherapy regimens, leading to a wide range in treatment cost. The understanding of NSCLC treatment patterns in Mexico will help to identify and address unmet needs.
Databáze: MEDLINE
Externí odkaz: